Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,1 USD | 0,00% | +1,85% | -24,14% |
12/03 | Rigel Pharmaceuticals kondigt benoeming aan van Lisa Rojkjaer als Chief Medical Officer | CI |
07/03 | RIGEL PHARMACEUTICALS, INC. : Citigroup herhaalt koopadvies | ZM |
Omzet 2024 * | 149 mln. 140 mln. | Omzet 2025 * | 192 mln. 180 mln. | Marktkapitalisatie | 193 mln. 180 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -14,96 mln. | Nettowinst (verlies) 2025 * | 18 mln. 16,83 mln. | EV/omzet 2024 * | 1,29 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1 x |
K/w-verhouding 2024 * |
-12,6
x | K/w-verhouding 2025 * |
12,9
x | Werknemers | 147 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,89% |
Recentste transcriptie over Rigel Pharmaceuticals, Inc.
1 week | +1,85% | ||
Lopende maand | -25,68% | ||
1 maand | -22,54% | ||
3 maanden | -14,73% | ||
6 maanden | +48,11% | ||
Lopend jaar | -24,14% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 01-04-00 |
Dean Schorno
DFI | Director of Finance/CFO | 61 | 29-05-18 |
Chief Tech/Sci/R&D Officer | - | 01-09-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gregg Lapointe
CHM | Chairman | 65 | 02-11-17 |
Gary Lyons
BRD | Director/Board Member | 73 | 01-10-05 |
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 01-04-00 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.02% | 509 M€ | -.--% | ||
0.02% | 0 M€ | 0,00% | - | |
0.00% | 9 M€ | -.--% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1,1 | 0,00% | 364 286 |
25-04-24 | 1,1 | -2,22% | 2 972 822 |
24-04-24 | 1,125 | -1,32% | 6 450 770 |
23-04-24 | 1,14 | +0,88% | 520 000 |
22-04-24 | 1,13 | +4,63% | 3 339 868 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-24,14% | 193 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |